Latest Insights - page 33 | BiopharmaTrend

North Bristol NHS Trust Becomes Reference Site for FUJIFILM’s Digital Pathology Platform

North Bristol NHS Trust has been named the first European reference site for FUJIFILM Healthcare’s SYNAPSE Pathology system, marking a continuation of their collaboration that began in 2022. The agreement …

Continue ›››

Inductive Bio Raises $25M to Scale AI Platform for Predicting Drug Behavior Before Synthesis

Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery. The round was led by Obvious Ventures, with participation …

Continue ›››

Flagship Launches Etiome with $50M to Use AI for Stage-Specific Drug Target Discovery

Flagship Pioneering has launched Etiome, a biotechnology start-up focused on identifying and drugging biomarkers that correspond to specific stages of disease progression. The company begins operations with $50 million in …

Continue ›››

Twist Bioscience Spins Out Atlas Data Storage with $155M to Commercialize DNA-Based Data Storage

Twist Bioscience has launched Atlas Data Storage as an independent company focused entirely on the development and commercialization of DNA data storage technologies. Atlas debuts with $155 million in seed …

Continue ›››

Lantern Pharma Advances AI-Guided Drug into Phase 1b/2 Trial for Triple Negative Breast Cancer

Lantern Pharma announced FDA clearance of its Investigational New Drug (IND) application for LP-184 in the treatment of triple negative breast cancer (TNBC). The planned Phase 1b/2 trial will evaluate …

Continue ›››

Recursion Reports Positive Early Trial Results for Familial Adenomatous Polyposis

Recursion has released early results from its ongoing Phase 1b/2 TUPELO trial evaluating REC-4881, an investigational MEK1/2 inhibitor, as a potential treatment for Familial Adenomatous Polyposis (FAP). FAP is a …

Continue ›››

How AI, Graphs, and GraphRAG Are Set to Revolutionize Alzheimer's Gene Research and Treatment

An estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s. Without major medical breakthroughs, that number is projected to rise to 13.8 million in the U.S. by …

Continue ›››

The Infrastructure Layer: 30 Platforms Powering Human-Relevant Drug Development

Infrastructure for large-scale biomedical data — from multi-omics to EHRs — is converging with a growing policy and business case for data-native drug development. In this article: Clinical Data & Real-World …

Continue ›››

No Clear Winner: 7-Year Brain Study Tests Rival Theories of Consciousness

A global team of researchers has carried out what may be the most ambitious attempt yet to test two of the most influential theories of consciousness: Integrated Information Theory (IIT) …

Continue ›››

Nurix Debuts Foundation Model to Predict Novel Binders for Undruggable Targets

Nurix Therapeutics presented new data at the 2025 AACR Annual Meeting supporting the capabilities of its DEL-AI platform—a machine learning–powered system designed to accelerate discovery of small molecule binders using …

Continue ›››

Eli Lilly Partners with Creyon Bio in up to $1B AI-Oligonucleotide Deal

Eli Lilly has signed a strategic partnership with Creyon Bio to develop AI-designed oligonucleotide therapeutics, committing $13 million upfront and up to $1 billion in performance-based milestone payments. The deal grants …

Continue ›››

NIH Launches Initiative to Prioritize Human-Based Research Technologies

The National Institutes of Health (NIH) has launched a new initiative to expand the use of human-based research technologies while reducing reliance on animal models, establishing a dedicated Office of …

Continue ›››